MARKET

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ
0.4020
-0.0080
-1.95%
After Hours: 0.4250 +0.023 +5.72% 18:02 02/03 EST
OPEN
0.4150
PREV CLOSE
0.4100
HIGH
0.4299
LOW
0.3900
VOLUME
303.75K
TURNOVER
0
52 WEEK HIGH
1.200
52 WEEK LOW
0.2900
MARKET CAP
13.51M
P/E (TTM)
-0.4530
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 3d ago
BRIEF-Plus Therapeutics Completes Enrollment In Second ReSPECT-LM Phase 1 Trial Cohort
Reuters · 4d ago
Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases
Benzinga · 4d ago
Plus Therapeutics (PSTV) Receives a Buy from Maxim Group
TipRanks · 01/19 19:15
BRIEF-Plus Therapeutics Announces First Patient Dosed In Mid-stage Study For Brain Cancer Treatment
Reuters · 01/18 13:56
Plus Therapeutics' Phase 2b Trial of Rhenium to Treat Recurrent Glioblastoma Doses First Patient
Plus Therapeutics' Phase 2b Trial of Rhenium to Treat Recurrent Glioblastoma Doses First Patient
MT Newswires · 01/18 08:14
Why Geron Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 01/05 13:01
BRIEF-Plus Therapeutics Says On Dec 9, Entered Settlement Deal With Lorem To Resolve A Previously Disclosed Lawsuit Stemming From Contractual Dispute
Reuters · 12/15/2022 22:07
More
About PSTV
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The Company is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The Company is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The Company also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.

Webull offers kinds of Plus Therapeutics Inc stock information, including NASDAQ:PSTV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTV stock methods without spending real money on the virtual paper trading platform.